Abstract
Carbonic anhydrases (CAs, EC 4.2.1.1) catalyze the fundamental reaction of CO2 hydration in all living organisms, being actively involved in the regulation of a plethora of patho/physiological processes. They represent a typical example of enzyme convergent evolution, as six genetically unrelated families of such enzymes were described so far. It is more than 70 years that synthetic compounds, mainly sulfonamides, have been used in clinical practice as diuretics and systemic acting antiglaucoma drugs. Recent studies using natural product libraries and isolated constituents from natural sources (such as fungi and plants) have disclosed novel chemotypes possessing carbonic anhydrase inhibition activities. These natural sources offer new opportunities in the search for new and more effective carbonic anhydrase inhibitors, and may serve as new leads for the design and development of future drugs.
This review will discuss the most recent advances in the search of naturally occurring products and their synthetic derivatives that inhibit the CAs and their mechanisms of action at molecular level. Plant extracts are not considered in the present review.
Keywords: Carbonic anhydrase inhibitors (CAIs), metalloenzymes, natural products, polyphenols, flavonoids.
Current Pharmaceutical Design
Title:An Update on Natural Products with Carbonic Anhydrase Inhibitory Activity
Volume: 22 Issue: 12
Author(s): Anastasia Karioti, Fabrizio Carta and Claudiu T. Supuran
Affiliation:
Keywords: Carbonic anhydrase inhibitors (CAIs), metalloenzymes, natural products, polyphenols, flavonoids.
Abstract: Carbonic anhydrases (CAs, EC 4.2.1.1) catalyze the fundamental reaction of CO2 hydration in all living organisms, being actively involved in the regulation of a plethora of patho/physiological processes. They represent a typical example of enzyme convergent evolution, as six genetically unrelated families of such enzymes were described so far. It is more than 70 years that synthetic compounds, mainly sulfonamides, have been used in clinical practice as diuretics and systemic acting antiglaucoma drugs. Recent studies using natural product libraries and isolated constituents from natural sources (such as fungi and plants) have disclosed novel chemotypes possessing carbonic anhydrase inhibition activities. These natural sources offer new opportunities in the search for new and more effective carbonic anhydrase inhibitors, and may serve as new leads for the design and development of future drugs.
This review will discuss the most recent advances in the search of naturally occurring products and their synthetic derivatives that inhibit the CAs and their mechanisms of action at molecular level. Plant extracts are not considered in the present review.
Export Options
About this article
Cite this article as:
Karioti Anastasia, Carta Fabrizio and Supuran T. Claudiu, An Update on Natural Products with Carbonic Anhydrase Inhibitory Activity, Current Pharmaceutical Design 2016; 22 (12) . https://dx.doi.org/10.2174/1381612822666151211094235
DOI https://dx.doi.org/10.2174/1381612822666151211094235 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
T Cell Receptor Bias in Humans
Current Immunology Reviews (Discontinued) The Impact of Coagulation and Fibrinolysis Cascades on the Development of Septic and Autoimmune Arthritis
Current Rheumatology Reviews Recombination Functions of Replication Protein A
Current Organic Chemistry Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango
Current Pharmaceutical Design Lipids and Their Derivatives: By-Products Used as Essential Building Blocks for Modern Drug Delivery Systems
Current Drug Targets Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Mutations in MicroRNA Genes and Their Binding Sites are Infrequently Associated with Human Colorectal Cancer in the Kashmiri Population
MicroRNA The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism The Potential of Acridine Carboxamide Pt Complexes as Anti-Cancer Agents : A Review
Anti-Cancer Agents in Medicinal Chemistry Inhibition of EGFR Signaling by N-cyclohexyl-2-(1-(phenylsulfonyl)piperidin-4-yl) acetamide
Anti-Cancer Agents in Medicinal Chemistry Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry Patents and the Development on Polymer based Nanomaterial (PAMAM Dendrimer) for Biomedical Applications
Recent Patents on Biomedical Engineering (Discontinued) A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia
Current Drug Safety An Insight into Purine, Tyrosine and Tryptophan Derived Marine Antineoplastic Alkaloids
Anti-Cancer Agents in Medicinal Chemistry Case Report of a Large Rhinolith Cast – A Frequently Missed Diagnosis
New Emirates Medical Journal Lactoferrin Suppresses Decreased Locomotor Activities by Improving Dopamine and Serotonin Release in the Amygdala of Ovariectomized Rats
Current Molecular Pharmacology Towards Multifunctional Synthetic Vectors
Current Gene Therapy Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research